<DOC>
	<DOCNO>NCT01408511</DOCNO>
	<brief_summary>A multicenter , open-label study evaluate adrenal suppression potential Mapracorat 0.1 % ointment adult atopic dermatitis .</brief_summary>
	<brief_title>HPA Axis Study Adults</brief_title>
	<detailed_description>Assessment safety , efficacy , pharmacokinetics adrenal suppression potential Mapracorat 0.1 % ointment adult atopic dermatitis .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Signed write informed consent Male female subject age &gt; = 18 year Diagnosis atopic dermatitis accord Hanifin Rajka Criteria Investigator 's Global Assessment ( IGA ) score 3 ( moderate ) 4 ( severe ) baseline Normal ACTH response start treatment Pregnancy lactation Clinically relevant disease , could interfere study conduct evaluation interpretation study result Concomitant medical dermatological disorder ( ) , could interfere study conduct evaluation interpretation study result Clinically manifest immunosuppressive disorder know history malignant disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>